Suman Bireddy, MD
Nephrology · Arlington, TXNPI 1093765299
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.8% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Amgen at 29.7% of the total. Reporting peaked in 2024 at $114 and has fallen 59.0% since, to $47 in 2025. That places this record below the midpoint for nephrology clinicians in TX, where the typical reported total is $1,420.
Across 16 payments — averaging $21.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$101
- Scpharmaceuticals Inc.$52
- Bayer$45
- Akebia Therapeutics Inc$40
- Mallinckrodt Hospital Products Inc.$32
- Novartis$30
- plus $39 from 2 others
What the payments were for
- Food & beverage$31593%
- Education$257%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 5 | $101 |
| Scpharmaceuticals Inc. | 2 | $52 |
| Bayer | 3 | $45 |
| Akebia Therapeutics Inc | 2 | $40 |
| Mallinckrodt Hospital Products Inc. | 1 | $32 |
| Novartis | 1 | $30 |
| GSK | 1 | $20 |
| Sanofi | 1 | $19 |
How this compares
$339 in reported general payments places this provider in the 20th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 13 | $48,136 |
| LokelmaSodium Zirconium Cyclosilicate | 12 | $8,990 |
| Sevelamer Carbonate | 36 | $6,596 |
| Nifedipine ErNifedipine | 66 | $2,344 |
| Hydralazine Hcl | 84 | $1,248 |
| Furosemide | 150 | $845 |
| Midodrine Hcl | 15 | $707 |
| Allopurinol | 57 | $434 |
| Metolazone | 12 | $407 |
| Torsemide | 17 | $362 |
| Carvedilol | 51 | $301 |
| Losartan Potassium | 44 | $294 |
| Lisinopril | 28 | $291 |
| Amlodipine Besylate | 33 | $191 |
| Labetalol Hcl | 11 | $184 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Arlington
- Hanna ThomasArlington$67K
- Abdul AbdellatifWebster$2.1M
- German HernandezEl Paso$1.3M
- Ankit MehtaDallas$1.1M
- Biff PalmerDallas$867K
- Gates ColbertDallas$828K
- Sreedhar MandayamHouston$752K
- Luis VelezSan Antonio$505K
- Anand ReddyOdessa$469K
- Christopher KwohHouston$467K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.